ARHGEF1

Across TCGA pan-cancer cohorts, ARHGEF1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ARHGEF1 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ARHGEF1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ARHGEF1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, HNSC, and COAD are the cancer types where ARHGEF1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.790	0.386	<.001	31	view →
HNSC	DFS	Tertile	III,IV	0.671	0.955	.003	23	view →
COAD	DFS	Median	IV	0.493	0.944	.031	18	view →
GBM	DFS	Tertile	All	0.671	0.882	.001	8	view →
LUAD	DFS	Quartile	All	0.789	0.492	.010	5	view →
UCEC	DFS	Quartile	All	0.798	0.959	.049	4	view →
LSCC	DFS	Median	All	0.627	0.805	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ARHGEF1–PDAC (OS)

Open the PDAC breakdown →